Skip to content
DataLookout
Menu

EMERGENCT07861152

Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Up to approximately 68 weeks

Secondary (7)

Concentrations of REGN24493 in serum
Serum Thyroid-Stimulating Hormone (TSH) levels
Serum free T4 (fT4) levels
Serum free T3 (fT3) levels
Serum total T3 (TT3) levels
Show 2 moreShow less
Occurrence of anti-drug antibody (ADA) to REGN24493 in serum
Magnitude of anti-drug antibody (ADA) to REGN24493 in serum

Arms and interventions

Dose EscalationExperimental
Placebo ComparatorPlacebo comparator

Drugs: REGN24493, Placebo